Form 4: CG Oncology Director Sells Shares Under 10b5-1 Plan

CG Oncology Director Leonard Post exercised options and sold 1,000 shares of common stock for $43.25 per share under a pre-arranged trading plan.

Summary

• Leonard E. Post, a Director of CG Oncology, Inc. (CGON), reported changes in beneficial ownership.
• On October 13, 2025, Mr. Post acquired 1,000 shares of common stock by exercising Director Stock Options at an exercise price of $0.60 per share.
• Concurrently, Mr. Post disposed of 1,000 shares of common stock at a price of $43.25 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Post on September 6, 2024.
• Following these transactions, Mr. Post's direct beneficial ownership of non-derivative common stock is 0 shares from this specific transaction, but he retains 118,077 fully vested Director Stock Options.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about it being based on new, undisclosed information. The director also realized a substantial profit from the option exercise.

Positives

• The director realized a significant profit by exercising options at $0.60 and selling shares at $43.25.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, undisclosed material information.

Negatives

• An insider selling shares, even if pre-planned, can sometimes be perceived as a negative signal by investors.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is specific to CG Oncology and does not directly reflect broader industry trends. However, insider trading activity is routinely monitored by investors across all industries as a potential indicator of management's perception of company value.

Stakeholder Impact

• Shareholders may observe this transaction as a director taking profits, which could lead to minor shifts in short-term sentiment, though the pre-planned nature reduces its signaling impact.

Key Dates

Recommendation

A single, pre-planned sale by a director, even if profitable, typically does not warrant a change in investment recommendation unless it represents a significant portion of their holdings or is part of a broader pattern of insider selling. Given the Rule 10b5-1 plan, this transaction is less indicative of a change in the director's fundamental view of the company's prospects. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring for further developments or patterns in insider activity.

Keywords

CGON, insider transaction, Form 4, stock option exercise, share sale, director, beneficial ownership, Rule 10b5-1